Below are the most recent publications written about "Non-alcoholic Fatty Liver Disease" by people in Profiles.
-
Sabet A. A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 May 02; 390(17):1632.
-
Min K, Yenilmez B, Kelly M, Echeverria D, Elleby M, Lifshitz LM, Raymond N, Tsagkaraki E, Harney SM, DiMarzio C, Wang H, McHugh N, Bramato B, Morrison B, Rothstein JD, Khvorova A, Czech MP. Lactate transporter MCT1 in hepatic stellate cells promotes fibrotic collagen expression in nonalcoholic steatohepatitis. Elife. 2024 Apr 02; 12.
-
Wuopio A, Baker BM, Koethe B, Goodman MD, Shin R, Bugaev N, Nepomnayshy D, Kim WC, Schnelldorfer T. Can Surgeons Reliably Identify Non-cirrhotic Liver Disease During Laparoscopic Bariatric Surgery? Obes Surg. 2024 Mar; 34(3):769-777.
-
Fantasia KL, Austad K, Mohanty A, Long MT, Walkey A, Drainoni ML. Safety-Net Primary Care and Endocrinology Clinicians' Knowledge and?Perspectives on Screening for Nonalcoholic Fatty Liver Disease: A?Mixed-Methods Evaluation. Endocr Pract. 2024 Mar; 30(3):270-277.
-
VoPham T, Cravero A, Feld LD, Green P, Feng Z, Berry K, Kim NJ, Vutien P, Mendoza JA, Ioannou GN. Associations of Race and Ethnicity with Hepatocellular Carcinoma, Decompensation, and Mortality in US Veterans with Cirrhosis. Cancer Epidemiol Biomarkers Prev. 2023 08 01; 32(8):1069-1078.
-
Heredia NI, Thrift AP, Ramsey DJ, Loomba R, El-Serag HB. Association of Diet Quality with Metabolic (Dysfunction) Associated Fatty Liver Disease in Veterans in Primary Care. Nutrients. 2023 Jun 01; 15(11).
-
de Carvalho Ribeiro M, Cho Y, Mehta J, Wang X, Babuta M, Copeland C, Hussein H, Catalano D, Wang Y, Szabo G. Protective role of cGAS in NASH is related to the maintenance of intestinal homeostasis. Liver Int. 2023 09; 43(9):1937-1949.
-
Ohkubo R, Mu WC, Wang CL, Song Z, Barthez M, Wang Y, Mitchener N, Abdullayev R, Lee YR, Ma Y, Curtin M, Srinivasan S, Zhang X, Yang F, Sudmant PH, Pisco AO, Neff N, Haynes CM, Chen D. The hepatic integrated stress response suppresses the somatotroph axis to control liver damage in nonalcoholic fatty liver disease. Cell Rep. 2022 12 13; 41(11):111803.
-
Thrift AP, Nguyen TH, Pham C, Balakrishnan M, Kanwal F, Loomba R, Duong HT, Ramsey D, El-Serag HB. The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting. Clin Gastroenterol Hepatol. 2023 05; 21(5):1252-1260.e5.
-
Guix?-Muntet S, Biquard L, Szabo G, Dufour JF, Tacke F, Francque S, Rautou PE, Gracia-Sancho J. Review article: vascular effects of PPARs in the context of NASH. Aliment Pharmacol Ther. 2022 07; 56(2):209-223.